A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus

NCT05407961 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of the investigational drug LY3532226 in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 90 people

Who can join Ages 18–70 · all sexes

Timeline Started 2022-06 · est. completion 2024-01

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT05407961 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 16 weeks excluding screening period for each part, respectively.

Treatments tested

LY3532226 Drug

Administered SC.
Placebo Drug

Administered SC.
Dulaglutide also known as Trulicity Drug

Administered SC.

Main thing measured	Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05407961 ↗